Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Austin Retina Associates, Austin, Texas +2 locations
Conditions: Anterior Uveitis
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: SouthWest Regional Cancer Center, Austin, Texas
Conditions: Diffuse Large B-cell Lymphoma
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: Lone Star Oncology - Austin, Austin, Texas
Conditions: Multiple Myeloma and Plasma Cell Neoplasm